XCUR - צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים Exicure

The lack of regular revenue due to a focus on R&D stands in contrast to critical delisting threats and the consequences of restructuring for Exicure, Inc. (XCUR). The rolling annual sales growth rate, with a recent value recorded as -100.40, helps resolve this conflict by objectively demonstrating revenue dynamics. The development of spherical nucleic acid platforms and partnerships with global corporations ensure the company's ultimate stability.
Exicure Inc. - פילוחים אנליטיים ומדדי מפתח (XCUR)

The metric is calculated as the percentage deviation of the current trailing twelve-month (TTM) revenue from the same period of the previous cycle. It measures the actual scaling dynamics of the business by excluding seasonal distortions. For Exicure, Inc. (XCUR), this rate reflects the efficiency of restoring commercial ties following the loss of patent protection. It is critical for investors to track the TTM sales volume change to assess market demand. This chart serves as an indicator of the resilience of the new intellectual property capitalization strategy.